Comparison of the Isotonic and Hypotonic Intravenous Maintenance Fluids In Term Newborns: Neofluid Study (NEOFLUID)

July 25, 2023 updated by: Funda Tuzun, Dokuz Eylul University

Comparison of the Effects of Isotonic and Hypotonic Intravenous Maintenance Fluids on Term Neonatal Babies Undergoing Intravenous Fluid Therapy: Multicenter Observational Neofluid Study

Considering the physiological changes in fluid and electrolyte balance and providing proper support are one of the important aspects of neonatal intensive care. Maintenance intravenous fluids are designed to maintain homeostasis when a patient is unable to uptake required water, electrolytes, and energy. Hypotonic fluids are still the most commonly prescribed IV fluids for pediatric hospitalized patients. However, previous studies, including children older than one month of age revealed that traditionally used hypotonic fluids may lead to hyponatremia.

Because of the absence of evidence-based data, there is currently no clear consensus on the optimal composition of maintenance intravenous fluid therapy in newborns, leading to wide practice variation.

The National Clinical Guideline Center (NICE) 2015 recommends the use of isotonic fluids in term newborn infants and some newborn centers has begun to use isotonic fluids since guidelines recommendations. Since the publication of the NICE guideline, no studies have addressed this topic.

In this prospective, observational , multicentric study, conventional hypotonic fluids containing sodium chloride (NaCl) < 130 mmol/L compared with isotonic fluids (containing NaCl between 131-154 mmol/L) in terms of the risk of hyponatremia, hypernatremia, plasma sodium (pNa) level change, treatment morbidities, hospitalization duration and mortality.

Study Overview

Study Type

Observational

Enrollment (Actual)

420

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • İzmir, Turkey, 35340
        • Dokuz Eylul University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 day to 1 month (Child)

Accepts Healthy Volunteers

N/A

Sampling Method

Probability Sample

Study Population

Hospitalized term newborns (>37 weeks) , requiring iv fluid treatment after 24 hour postnatal age

Description

Inclusion Criteria are:

  • Term newborns (>37 + 0/7 weeks) aged 24 hours to 30 days with a normal baseline serum sodium level between 135-145 mmol/L,with a treatment plan to include IV fluids at > 50% of maintenance
  • Infants not received parenteral fluids in the last 24 hours before participation
  • Infants receiving IV fluid administration at 50% to 100% of maintenance

Exclusion Criteria:

  • Newborns with diagnoses that required specific fluid tonicity and volumes such as:

    • Severe dehydration presenting with shock
    • Syndrome of inappropriate antidiuretic hormone secretion (SIADH)
    • Renal insufficiency
    • Adrenal insufficiency
    • Diabetes mellitus and diabetes insipidus
    • Hypoxic ischemic encephalopathy
    • Major congenital anomaly
    • Patients receiving diuretic therapy
    • Patients with obvious edema
    • Heart or liver failure, portal hypertension with acid
    • Pre-post operative patients
    • Infants receiving total parenteral nutritional therapy
    • Other: all conditions that require non-standard liquid content and quantities

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Isotonic fluid

Group, received isotonic maintenance fluid containing NaCl between 131 to 154 mmol/L such as:

  • Dextrose 5% in 0.9% NaCl,
  • Intravenous fluid containing NaCl between 131 to 154 mmol/L
Isotonic group will be given fluids containing 131-154 mmol/L Sodium Chloride
Other Names:
  • B05BB02, 0.9% NaCl/Dextrose 5%
Hypotonic fluid

Group, received hypotonic maintenance fluid containing NaCl < 130 mmol/L such as:

  • Dextrose 5 % in 0.02 % NaCl,
  • Dextrose 5% in 0.033 % NaCl
  • Dextrose 5% in 0.045 % NaCl
  • Intravenous fluid containing NaCl < 130 mmol/L

Hypotonic group will be given fluids containing lower than 130 mmol/L :

Dextrose 5% in 0.2% Sodium Chloride, or Dextrose 5% in 0.33 % Sodium Chloride,or Dextrose 5% in %0.45 Sodium Chloride, or Intravenous fluid containing Sodium Chloride < 130 mmol/L

Other Names:
  • B05BB02, 0.45% NaCl/5% dextrose
  • B05BB02, 0.33 % NaCl/5% dextrose
  • B05BB02, 0.20 % NaCl/5% dextrose

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in mean plasma Na
Time Frame: 24 hours after the intervention
Change in mean plasma sodium levels per hour (∆pNa mmol/L/hour)
24 hours after the intervention
Rate of development of hyponatremia
Time Frame: during the intervention
Plasma sodium (pNa) level <135 mmol/L
during the intervention
Rate of development of hypernatremia
Time Frame: during the intervention
Plasma sodium (pNa) level >145 mmol/L
during the intervention

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Weight in kilograms
Time Frame: during the intervention
weight gain
during the intervention
length of stay
Time Frame: during the intervention
hospitalisation day
during the intervention
mortality
Time Frame: during the intervention
mortality due to complications of administered fluid
during the intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 30, 2020

Primary Completion (Actual)

December 31, 2022

Study Completion (Actual)

June 30, 2023

Study Registration Dates

First Submitted

February 4, 2021

First Submitted That Met QC Criteria

March 1, 2021

First Posted (Actual)

March 4, 2021

Study Record Updates

Last Update Posted (Actual)

July 27, 2023

Last Update Submitted That Met QC Criteria

July 25, 2023

Last Verified

July 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Fluid Therapy

Clinical Trials on Intravenous isotonic fluid - NaCl 131-154 mmol/L in 5% dextrose

3
Subscribe